Limited-Stage Small-Cell Lung Cancer

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.

Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.

Durvalumab extended OS and PFS compared with placebo for patients with limited-stage small cell lung cancer, according to topline data released by the agent’s manufacturer.